A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.

Hongming Pan,Tianshu Liu,Jason Tsai,Yapeng Zhao

A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.

2019

Hongming Pan
Tianshu Liu
Jason Tsai
Yapeng Zhao

3061Background: Telatinib (EOC315) is a highly selective inhibitor of VEGFR/PDGFR (VEGFR 1-3, PDGFR-β, and c-Kit tyrosine kinases). This phase I study was to assess the safety, tolerability, and ph...

Keywords:

VEGF receptors
Pathology
Oncology
Pharmacokinetics
Medicine
Tolerability
Internal medicine
safety tolerability
multiple dose
Tyrosine kinase
Pharmacology
highly selective
Platelet-derived growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations